Ironwood Pharmaceuticals, Inc.
IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as uā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.14
Price-6.83%
-$0.23
1Y
Price
Market Cap
$510.811m
Small
Price/Earnings 3y Avg5y Avg
17.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+54.7%
EBITDA Margin+27.7%
Net Profit Margin-17.7%
Free Cash Flow MarginRevenue
$308.519m
-12.2%
1y CAGR-8.3%
3y CAGR-6.4%
5y CAGREarnings
-$7.885m
-996.0%
1y CAGR-522.8%
3y CAGR-408.8%
5y CAGREPS
-$0.05
-600.0%
1y CAGR-423.9%
3y CAGR-335.4%
5y CAGRBook Value
-$308.162m
$342.946m
Assets$651.108m
Liabilities$598.669m
DebtDebt to Assets
174.6%
7.5x
Debt to EBITDAFree Cash Flow
$29.936m
-71.0%
1y CAGR-49.2%
3y CAGR-35.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company